Be Biopharma unveils promising preclinical results for hypophosphatasia treatment using engineered B cell medicines
Be Biopharma, Inc. has presented groundbreaking preclinical findings that underscore the potential of Engineered B Cell Medicines (BCMs) as a novel therapeutic avenue for Hypophosphatasia (HPP), a rare genetic disorder. During the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting, the company showcased how BCMs, developed using CRISPR/Cas9 precision gene engineering and […]